Foghorn Therapeutics Inc.

NasdaqGM:FHTX Voorraadrapport

Marktkapitalisatie: US$459.2m

Foghorn Therapeutics Beheer

Beheer criteriumcontroles 3/4

De CEO Foghorn Therapeutics is Adrian H. Gottschalk, benoemd in May2017, heeft een ambtstermijn van 7.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.50M, bestaande uit 23.1% salaris en 76.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.92% van de aandelen van het bedrijf, ter waarde $ 4.25M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.2 jaar en 7.3 jaar.

Belangrijke informatie

Adrian H. Gottschalk

Algemeen directeur

US$2.5m

Totale compensatie

Percentage CEO-salaris23.1%
Dienstverband CEO7.5yrs
Eigendom CEO0.9%
Management gemiddelde ambtstermijn1.2yrs
Gemiddelde ambtstermijn bestuur7.3yrs

Recente managementupdates

Recent updates

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 28% Share Price Plunge Could Signal Some Risk

Oct 22
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 28% Share Price Plunge Could Signal Some Risk

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares Climb 35% But Its Business Is Yet to Catch Up

Sep 01
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares Climb 35% But Its Business Is Yet to Catch Up

Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 27% But Growth Is Lacking

Jul 17
Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 27% But Growth Is Lacking

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target

May 09
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target

Companies Like Foghorn Therapeutics (NASDAQ:FHTX) Are In A Position To Invest In Growth

Apr 12
Companies Like Foghorn Therapeutics (NASDAQ:FHTX) Are In A Position To Invest In Growth

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Share Price Boosted 71% But Its Business Prospects Need A Lift Too

Feb 22
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Share Price Boosted 71% But Its Business Prospects Need A Lift Too

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Fly 33% But Investors Aren't Buying For Growth

Dec 13
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Fly 33% But Investors Aren't Buying For Growth

Need To Know: Analysts Are Much More Bullish On Foghorn Therapeutics Inc. (NASDAQ:FHTX) Revenues

Nov 07
Need To Know: Analysts Are Much More Bullish On Foghorn Therapeutics Inc. (NASDAQ:FHTX) Revenues

Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans

Jun 14
Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans

Foghorn Therapeutics: Selling For Less Than Cash Value

Oct 10

Foghorn stock slumps 18% as FDA places full clinical hold on blood cancer trial of FHD-286

Aug 23

Foghorn Therapeutics GAAP EPS of -$0.66 misses by $0.07, revenue of $4.49M

Aug 09

Foghorn: Big Pharma Interest, Resolvable Clinical Hold Equals Opportunity

Jun 02

We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely

Apr 13
We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely

Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?

Feb 27
Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?

Analyse CEO-vergoeding

Hoe is Adrian H. Gottschalk's beloning veranderd ten opzichte van Foghorn Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$86m

Mar 31 2024n/an/a

-US$93m

Dec 31 2023US$3mUS$579k

-US$98m

Sep 30 2023n/an/a

-US$103m

Jun 30 2023n/an/a

-US$115m

Mar 31 2023n/an/a

-US$112m

Dec 31 2022US$5mUS$575k

-US$109m

Sep 30 2022n/an/a

-US$109m

Jun 30 2022n/an/a

-US$109m

Mar 31 2022n/an/a

-US$105m

Dec 31 2021US$4mUS$540k

-US$101m

Sep 30 2021n/an/a

-US$93m

Jun 30 2021n/an/a

-US$85m

Mar 31 2021n/an/a

-US$78m

Dec 31 2020US$3mUS$479k

-US$69m

Sep 30 2020n/an/a

-US$63m

Jun 30 2020n/an/a

-US$58m

Mar 31 2020n/an/a

-US$54m

Dec 31 2019US$1mUS$465k

-US$51m

Compensatie versus markt: De totale vergoeding ($USD 2.50M ) Adrian H. } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.42M ).

Compensatie versus inkomsten: De vergoeding van Adrian H. is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.


CEO

Adrian H. Gottschalk (48 yo)

7.5yrs

Tenure

US$2,503,942

Compensatie

Mr. Adrian H. B. Gottschalk serves as President, Chief Executive Officer and a Director of Foghorn Therapeutics Inc. since May, 2017. Prior to joining Foghorn and since 2004, Mr. Gottschalk worked at Bioge...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Adrian H. Gottschalk
President7.5yrsUS$2.50m0.92%
$ 4.2m
Steven Bellon
Chief Scientific Officer2.8yrsUS$1.19m0.27%
$ 1.3m
Alfonso Cardama
Chief Medical Officer1.2yrsUS$1.84mgeen gegevens
Gerald Crabtree
Founder & Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Kristian Humer
Chief Financial Officerless than a yeargeen gegevensgeen gegevens
Michael LaCascia
Chief Legal Officer4yrsUS$1.99m0%
$ 0
Saurabh Sewak
Vice President of Corporate Development2.8yrsgeen gegevensgeen gegevens
Carlos Costa
Chief People Officerno datageen gegevensgeen gegevens
Karin Hellsvik
Chief of Staff to the CEOless than a yeargeen gegevensgeen gegevens
Anna Rivkin
Chief Business Officerless than a yeargeen gegevensgeen gegevens
Michael Garcia-Webb
VP & Chief of Staff Researchless than a yeargeen gegevensgeen gegevens

1.2yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van FHTX wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.2 jaar), wat duidt op een nieuw team.


Bestuursleden

NaamPositieTenureCompensatieEigendom
Adrian H. Gottschalk
President7.5yrsUS$2.50m0.92%
$ 4.2m
Gerald Crabtree
Founder & Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
B. Parshall
Independent Director2.3yrsUS$157.65k0%
$ 0
Balkrishan Gill
Independent Director7.3yrsUS$159.07k0.062%
$ 282.7k
Douglas Cole
Founder & Independent Chairman of the Board9.1yrsUS$184.57k0%
$ 0
Charles Sawyers
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
David Schenkein
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Anthony Kouzarides
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Adam Koppel
Independent Director7.3yrsUS$153.07k0%
$ 0
Michael Mendelsohn
Independent Director7.6yrsUS$154.57k0%
$ 0
Scott Biller
Independent Director4.8yrsUS$145.57k0%
$ 0
Cigall Kadoch
Member of Scientific Advisory Board2.2yrsUS$252.52k6.55%
$ 30.1m

7.3yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van FHTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.3 jaar).